Prof Tony Mok speaks to ecancer about the new data from rare EGFR alterations in NSCLC from WCLC 2020 virtual meeting. He initially shares his expertise on the latest data and discussions from the WCLC conference on the treatment of patients with NSCLC with EGFR exon 20 insertion mutations.
He then talks about the results from EXCLAIM and pooled platinum-pre-treated patient populations who have NSCLC with EGFR exon 20 insertions and are treated with mobocertinib. He explains the efficacy of this drug.
Then he moves on to talk about amivantamab in post-platinum EGFR exon 20 insertion mutant non-small cell lung cancer. He further talks about the best practice in the management of these patients including diagnosis, treatment options and sequencing.
Prof Mok in the end, talks about the other latest data and developments presented at other conferences regarding NSCLC with EGFR mutations.
ecancer's filming has been kindly supported by Takeda through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.